PMID- 28195558
OWN - NLM
STAT- MEDLINE
DCOM- 20180730
LR  - 20181113
IS  - 2040-2058 (Electronic)
IS  - 1359-6535 (Print)
IS  - 1359-6535 (Linking)
VI  - 22
IP  - 6
DP  - 2017
TI  - Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in 
      HIV-HBV coinfection.
PG  - 523-527
LID - 10.3851/IMP3136 [doi]
AB  - BACKGROUND: In HBV-infected patients, hepatitis B e antigen (HBeAg) 
      seroconversion is associated with better outcomes. Interleukin-18 (IL-18) 
      controls hepatitis B replication in a mouse model. However, its role in treatment 
      response in HIV-HBV-coinfected patients is unknown. METHODS: We enrolled 35 
      treatment-naive, HBeAg-positive, HIV-HBV-coinfected patients. HBV DNA, HIV RNA, 
      CD4(+) T-cell count, HBV surface antigen (HBsAg) quantification (qHBsAg), HBeAg 
      quantification (qHBeAg) and IL-18 levels were measured prior to, at 24 and 48 
      weeks of HBV-active combination antiretroviral therapy (cART). Multivariate 
      Poisson regression models with robust standard errors were used to determine 
      factors associated with HBeAg seroconversion. RESULTS: Twenty-one patients 
      received tenofovir (TDF) + lamivudine (3TC) based cART while 14 patients received 
      3TC-based cART. After 48 weeks of treatment, 10 patients experienced HBeAg 
      seroconversion. Compared with non-seroconverters, seroconverters had higher 
      median HIV RNA (5.22 versus 4.58 log copies/ml; P=0.030), lower median qHBsAg 
      (3.97 versus 4.76 log IU/ml; P=0.011), lower median qHBeAg (1.61 versus 3.01 log 
      PEIU/ml; P=0.004) and marginally higher median IL-18 (2.70 versus 2.53 log pg/ml; 
      P=0.068) prior to ART. In the multivariate regression, higher baseline IL-18 
      (adjusted relative risk [aRR] 2.99 per 1 log pg/ml increase; P=0.035), high HIV 
      RNA (aRR 1.84 per 1 log copies/ml; P=0.029) and low qHBeAg (aRR 0.71 per 1 log 
      PEIU/ml; P=0.029) were significantly associated with HBeAg seroconversion. 
      CONCLUSIONS: In HIV-HBV-coinfected patients with HBeAg positivity, higher IL-18 
      levels, HIV RNA load, as well as low qHBeAg prior to cART were associated with 
      HBeAg seroconversion.
FAU - Li, Yijia
AU  - Li Y
AD  - Department of Infectious Diseases, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
AD  - Present address: University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
FAU - Xie, Jing
AU  - Xie J
AD  - Department of Infectious Diseases, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
AD  - Clinical Immunology Center, Chinese Academy of Medical Sciences, Beijing, China.
FAU - Wang, Huanling
AU  - Wang H
AD  - Department of Infectious Diseases, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Han, Yang
AU  - Han Y
AD  - Department of Infectious Diseases, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Wang, Nidan
AU  - Wang N
AD  - Department of Infectious Diseases, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Thio, Chloe L
AU  - Thio CL
AD  - Division of Infectious Diseases, Department of Medicine, Johns Hopkins 
      University, Baltimore, MD, USA.
FAU - Li, Taisheng
AU  - Li T
AD  - Department of Infectious Diseases, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
AD  - Clinical Immunology Center, Chinese Academy of Medical Sciences, Beijing, China.
LA  - eng
GR  - P30 AI094189/AI/NIAID NIH HHS/United States
GR  - R01 AI106586/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20170214
PL  - England
TA  - Antivir Ther
JT  - Antiviral therapy
JID - 9815705
RN  - 0 (Biomarkers)
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (Interleukin-18)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adult
MH  - Antiretroviral Therapy, Highly Active
MH  - Biomarkers
MH  - CD4 Lymphocyte Count
MH  - *Coinfection
MH  - Female
MH  - HIV Infections/*blood/diagnosis/drug therapy/virology
MH  - Hepatitis B/*blood/diagnosis/drug therapy/virology
MH  - Hepatitis B e Antigens/*blood
MH  - Humans
MH  - Interleukin-18/*blood
MH  - Male
MH  - Middle Aged
MH  - RNA, Viral
MH  - *Seroconversion
MH  - Viral Load
PMC - PMC5561518
MID - NIHMS893927
COIS- Disclosure statement: Conflicts of Interest: Other authors have no conflicts of 
      interest.
EDAT- 2017/02/15 06:00
MHDA- 2018/07/31 06:00
PMCR- 2018/02/14
CRDT- 2017/02/15 06:00
PHST- 2017/02/07 00:00 [accepted]
PHST- 2017/02/15 06:00 [pubmed]
PHST- 2018/07/31 06:00 [medline]
PHST- 2017/02/15 06:00 [entrez]
PHST- 2018/02/14 00:00 [pmc-release]
AID - 10.3851/IMP3136 [doi]
PST - ppublish
SO  - Antivir Ther. 2017;22(6):523-527. doi: 10.3851/IMP3136. Epub 2017 Feb 14.